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ABSTRACT
Idiopathic inflammatory myopathies (IIM) include the
main subgroups polymyositis (PM), dermatomyositis
(DM), inclusion body myositis (IBM) and juvenile DM
( JDM). The mentioned subgroups are characterised by
inflammation of skeletal muscles leading to muscle
weakness and other organs can also be affected as
well. Even though clinically significant heart
involvement is uncommon, heart disease is one of the
major causes of death in IIM. Recent studies show an
increased prevalence of traditional cardiovascular risk
factors in JDM and DM/PM, which need attention. The
risk of developing atherosclerotic coronary artery
disease is increased twofold to fourfold in DM/PM.
New and improved diagnostic methods have in recent
studies in PM/DM and JDM demonstrated a high
prevalence of subclinical cardiac involvement,
especially diastolic dysfunction. Interactions between
proinflammatory cytokines and traditional risk factors
might contribute to the pathogenesis of cardiac
dysfunction. Heart involvement could also be related to
myocarditis and/or myocardial fibrosis, leading to
arrhythmias and congestive heart failure, demonstrated
both in adult and juvenile IIM. Also, reduced heart rate
variability (a known risk factor for cardiac morbidity
and mortality) has been shown in long-standing JDM.
Until more information is available, patients with IIM
should follow the same recommendations for
cardiovascular risk stratification and prevention as for
the corresponding general population, but be aware
that statins might worsen muscle symptoms mimicking
myositis relapse. On the basis of recent studies, we
recommend a low threshold for cardiac workup and
follow-up in patients with IIM.
INTRODUCTION
Idiopathic inﬂammatory myopathies (IIMs)
are a heterogeneous group of diseases char-
acterised by proximal muscle weakness and
inﬂammatory changes in skeletal muscle.
Adults or children can be affected, and in
adult onset IIM, cardiovascular complications
represent a major cause of death. However,
there is limited information on heart involve-
ment in IIM, both due to the rarity of the
diseases and because manifest cardiac com-
plications in these patients are uncommon.
In other rheumatic diseases, like rheumatoid
arthritis (RA) and systemic lupus erythemato-
sus (SLE), cardiac involvement is well docu-
mented.1–3 More recently, registry-based
studies reported associations between athero-
sclerosis and rare rheumatic and auto-
immune diseases, including IIM.4 5 Whether
atherosclerosis is the driving force of the
cardiac involvement in IIM or mechanisms
such as myocardial inﬂammation, systemic
inﬂammation or small vessel vasculitis play
equally important roles remains unknown.
Historically, cardiac involvement in IIM has
been demonstrated by ECG,6–8 continuous
electrocardiographic monitoring9–11 and aut-
opsies.12 13 Today, new cardiac imaging
modalities such as Tissue Doppler imaging
(TDI) by echocardiography,14–18 Cardiac MR
(CMR),19 99mtechnetium pyrophosphate
(99mTc-PYP) scintigraphy18 20 21 and coronary
artery calciﬁcation on CT scan22 can detect
subtle cardiac abnormalities. Owing to their
high sensitivity, these methods often suggest
a higher frequency of heart disease in IIM
than what is clinically evident. However,
despite this discrepancy, subclinical cardiac
pathology might represent early stages in
Key messages
▸ Idiopathic inflammatory myopathies (IIMs) are
associated with increased risk of cardiac
involvement mainly due to atherosclerosis and
myocarditis.
▸ A low threshold for cardiac workup and
follow-up in IIM is recommended.
▸ Monitor carefully when using statins in IIM:
statins may worsen muscle symptoms mimick-
ing myositis relapse.
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cardiac remodelling that will later manifest as clinical
heart disease, and can therefore not be ignored. Further
research is needed to clarify if subclinical disease will
eventually develop into clinically manifest cardiac
disease.23
Beyond general guidelines for cardiac diseases, spe-
ciﬁc recommendations for treatment or cardiac
follow-up of patients with IIM are non-existing. This
review summarises current evidence of cardiac complica-
tions in patients with the IIM subgroups polymyositis
(PM), dermatomyositis (DM), inclusion body myositis
(IBM) and juvenile IIM, where juvenile dermatomyositis
( JDM) is by far the most common subgroup. We will
also discuss possible disease mechanisms and what make
these patients particularly vulnerable, beyond the trad-
itional cardiovascular (CV) risk factors.
CARDIAC MORTALITY
The three major causes of cardiac mortality in patients
with IIM24 are similar to those of the population in
general: congestive heart failure, myocardial infarction
and arrhythmias. The reported mortality due to cardiac
involvement in adult onset IIM varies substantially in the
literature.25–30 Eleven by 20 (55%) of the deaths were
due to cardiac aetiology in a Hungarian longitudinal
study,26 36% of 149 deaths were due to circulatory
causes (not further speciﬁed) in a register-based Finnish
study, whereas 12/87 (14%) deaths were due to cardiac
causes in a recent population-based Norwegian study.31
Also, in retrospective follow-up studies on patients with
PM and DM, cardiac disease was one of the four most
frequent causes of death.32 33 The discrepancies
between the studies regarding aetiology of deaths may
be due to variable study designs and populations, vari-
able deﬁnitions of cardiac involvement, limited numbers
of patients in some of the series and studies performed
at different time periods and decades.
Not surprisingly, cardiac disease has been associated
with poor prognosis: in one study, 9 of 28 patients
(32%) with PM or DM and cardiac involvement died
within 8 years, whereas only 4 of the remaining 48
patients (8%) died during the same period.34 In juvenile
IIM, a Canadian study reported cardiac involvement in
3/17 reported deaths, but these patients also had
involvement of other organ systems.35
TRADITIONAL CARDIOVASCULAR RISK FACTORS
Increasing evidence suggests that traditional CV risk
factors (including diabetes, hypertension, dyslipidaemia,
obesity and smoking) are more prevalent in adult onset
IIM than in the general population (table 1); this has
especially been found for abdominal obesity.22 36 37
Increased prevalence of hypertension and dyslipidaemia
has also been shown in untreated patients with IIM,38 39
which indicates an effect of the disease per se in add-
ition to a possible effect of long-term glucocorticoid
treatment. Also in JDM, hypertension and dyslipidaemia
have been demonstrated (table 1).40–42 These ﬁndings
are in line with RA43 and SLE.44
The potential inﬂuence of and associations between
traditional CV risk factors, disease-speciﬁc parameters
and cardiac disease in IIM have so far only been
addressed in one study.22 In this study, traditional CV
risk factors and severe coronary artery calciﬁcation
(CAC) were commonly found in patients with PM/DM.
However, severe CAC was not associated with PM/DM
per se, but rather with age and smoking in these
patients. Thus, clinicians should pay attention to the
presence of traditional CV risk factors.
CLINICAL HEART INVOLVEMENT
Cardiac dysfunction and heart failure
Heart failure is a clinical syndrome with characteristic
symptoms and physical ﬁndings, while ‘cardiac dysfunc-
tion’ is a condition of cardiac pathology demonstrated
by various cardiac imaging techniques, but without clin-
ical symptoms. Systolic heart failure/dysfunction is due
to impaired left ventricular contraction and results in
reduced left ventricular ejection fraction (EF). In dia-
stolic heart failure/dysfunction, left ventricular EF is
normal, but pathological stiffness of the left ventricle
causes a restricted ﬁlling pattern. The symptoms of sys-
tolic and diastolic heart failure are indistinguishable.
Cardiac function is quickly and well assessed by echocar-
diography. The common deﬁnition of systolic dysfunc-
tion is left ventricular EF<40%. Diastolic dysfunction, on
the other hand, is deﬁned as E/é>14 (E, early diastolic
transmitral ﬂow; é early diastolic tissue velocity) and
normal EF (>50).45
Presence of severe systolic heart failure in adult onset
IIM is well documented in case reports.46–56 However,
controlled studies have not demonstrated increased
prevalence of systolic or diastolic heart failure in IIM
(table 2). On the other hand, controlled studies have
shown diastolic dysfunction in adult onset IIM with
impaired E/e’, but no evidence of systolic dysfunction
(table 2).14 15 18 57
In JDM, diastolic dysfunction was found in 22% of
patients after a median of 17 years from disease onset
(table 2)16 in addition to impaired systolic function (low
long axis strain assessed by echocardiography) compared
to age-matched and sex-matched controls (table 2).17
Whether systolic and diastolic heart failure represent
the two extremes on a continuum of cardiac damage58
or whether they are two separate entities, is still a matter
of debate.59 Interestingly, many of the referred IIM
studies showed an independent association between dia-
stolic dysfunction and disease duration,14–16 18 57 suggest-
ing at least diastolic cardiac involvement to be a
long-term complication of IIM, and only follow-up
studies can show if these patients develop heart failure.
Thus, the ﬁndings of diastolic dysfunction in IIM need
attention, since cardiac dysfunction may be seen as an
asymptomatic state on the road to clinically overt heart
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Table 1 Demographic and traditional cardiovascular risk factors of patients with IIM
Author, year Group n F/M n Age (years) HT % Smoke % DB % Obese, % DL % BMI kg/m2 PG† TC† LDLc† HDLc† TG†
Coyle, 200940 JDM 17 14/3 4.6-16.4 NA 0 0 23.5 47.1 19.7 ∼ 85 ∼
mg/dL
165 ∼
mg/dL
106∼
mg/dL
39 ∼
mg/dL
115 ∼
mg/dL
de Moraes, 201336 DM 84
105
67/17
83/22
41.5
42.0
47.6*
18.1
10.7
11.4
17.9*
1.0
NA 67.9*
49.5
27.5*
25.4
84*∼
80 ∼
mg/dL
180 ∼
187 ∼
mg/dL
88 ∼
113 ∼
mg/dL
49*∼
54 ∼
mg/dL
119*∼
86 ∼
mg/dL
de Souza, 201437 PM
Controls
35
70
27/8
54/16
49.7
48.7
45.7*
27.1
14.3
17.1
34.3*
4.3
NA 71.4*
51.4
27.5
26.0
91* ∼
81 ∼
mg/dL
196 ∼
194 ∼
mg/dL
111 ∼
122 ∼
mg/dL
57
55
mg/dL
149* ∼
99
mg/dL
Diederichsen 201422 PM/DM
Controls
76
48
49/27
32/16
60.0
59.4
71*
42
25
17
13*
0
33*
10
88¶*
73
27.6
26.0
6.5
6.0
5.6
5.4
3.3
3.1
1.6
1.7
1.5*
1.1
Eimer, 201141 JDM
Controls
8
15
3/5
6/9
38
37
NA 25
0
NA NA NA 23 ∼
24 ∼
94 ∼
92 ∼
mg/dL
NA 102* ∼
113 ∼
mg/dL
40* ∼
53 ∼
mg/dL
75 ∼
66 ∼
mg/dL
Schwartz, 201442 JDM
Controls
59
59
36/23
36/23
21.5
21.6
12*
0
23
17
0
0
NA NA 22.3
22.5
NA 4.2*
4.6
2.3*
2.7
1.2*
1.5
NA
Wang, 201338 DM‡
Controls
41
41
30/11
30/11
44.6
42.4
0
0
NA 0
0
NA 70.7¤
NA
NA NA 4.1
3.9
2.5
2.3
1.1*
1.3
2.2*
1.1
Wang, 201357 PM§
Controls
71
71
56/15
56/15
46.9
46.2
0
0
NA 0
0
NA NA NA 5.0
5.1
4.8
4.7
2.2*
1.8
2.0*
2.4
1.7*
1.3
Wang, 201439 PM‡
Controls
60
60
44/16
44/16
42.9
42.9
0
0
10
10
0
0
NA 47¤*
20
22.7
22.1
NA 4.1*
4.7
2.4*
2.7
0.9*
1.5
1.9*
1.3
Wang, 201414 DM§
Controls
51
51
43/8
43/8
44.1
44.4
0
0
NA 0
0
NA NA NA 4.8
4.8
4.8
4.8
2.9
2.7
1.4
1.5
1.7*
1.4
*p<0.05; JDM: juvenile dermatomyositis;.
†Units are mmol/L unless otherwise indicated and values are mean unless marked with ∼=median.
‡Untreated patients without hypertension, diabetes and cardiovascular heart disease.
§Patients without hypertension, diabetes and cardiovascular heart disease.
¶Hypercholesterolemia.
¤hypertriglyceridemia.
BMI, body mass index; DL, dyslipidaemia; DM, diabetes mellitus; DM: dermatomyositis; F/M, female/male; HDLc, high-density lipoprotein cholesterol; HT, hypertension; IIM, idiopathic
inflammatory myopathies; LDLc, low-density lipoprotein cholesterol; NA, not available; PG, plasma glucose; PM: polymyositis; TC, total cholesterol; TG, triglycerides.
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failure. However, whereas a number of treatment
options exist for systolic heart failure, no therapy has yet
proven effective in diastolic heart failure. It is not known
if diastolic dysfunction/heart failure can be prevented
by early disease control.
Coronary artery disease
The suggested main mechanism of cardiovascular
involvement in IIM is atherosclerosis in the
coronary arteries (ﬁgure 1). In 2014,60 Ungprasert et al
conducted a systematic review and meta-analysis of
published observational studies addressing risk of
coronary artery disease in adult onset IIM. Four studies,
all using registry-based databases, were included4 61–63
and demonstrated an increased risk of CAD with a
pooled risk-ratio of 2.24 (CI 1.02 to 4.92). However,
the only case–control study included in Ungprasert’s
review did not reveal an increased risk of CAD. Recently,
a large population-based retrospective study with
incident IIM cases from Canada reported an increased
risk of myocardial infarction in dermatomyositis and
polymyositis (nearly three and fourfold, respectively),
after controlling for age, sex and use of corticosteroids
and non-steroidal anti-inﬂammatory drugs.64 The risk
for both groups was highest in the ﬁrst year after
diagnosis.
Figure 1 Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation
may either have a direct effect on the myocardium or make the heart more susceptible to traditional risk factors. In the heart,
disease can occur in the pericardium, coronary arteries or the myocardium, and arrhythmias can appear. Myocardial disease can
result in diastolic or systolic dysfunction, and when clinical symptoms arise, the patient has developed heart failure. Myocardial
disease may result in arrhythmias, or they can occur as a result of inflammation directly influencing cardiomyocyte function. Both
arrhythmias and coronary artery disease, such as myocardial infarction, can directly result in heart failure.
4 Schwartz T, et al. RMD Open 2016;2:e000291. doi:10.1136/rmdopen-2016-000291
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Table 2 Echocardiographic findings of studies including tissue Doppler imaging
Author, year Group
Participants
(n)
F/M
(n)
Age
(years)
LV diastolic
dysfunction
(%)†
e0
(cm/s)†
E/ e0
ratio†
LV systolic
dysfunction
(%)†
LV EF
(%)†
Long-axis
strain
(%)†
Diederichsen 201521 IIM††
Controls
14
14
8/6
8/6
59.5
61.0
7
0
10.5
10.9
7.8
6.8
15
0
69
65
NA
Diederichsen 201518 PM/DM
Controls
76
48
49/27
32/16
60.0
59.4
63*
27
10.0*
11.0
8* ∼
7 ∼
8
2
65
65
NA
Lu, 201315 PM/DM‡
Controls
46
21
31/15
11/10
31.1
35.0
48
NA
10.5*
12.7
8.3*
6.8
NA 64.2
64.7
NA
Schwartz 2011
+201416 17
JDM
Controls
59
59
36/23
36/23
21.5∼
21.6∼
22*
0
11.3*
12.4
8.0*
7.1
Yes§ 63.2
62.5
16.6*
17.7
Wang 201357 PM‡
Controls
71
71
56/15
56/15
46.9
46.2
59.2
NA
7.5*
9.1
10.4*
8.7
0
0
67.7
67.1
NA
Wang, 201414 DM‡
Controls
51
51
43/8
43/8
44.1
44.4
76.5*
52.9
7.8*
9.3
9.9*
8.7
0
0
66.5
68.2
NA
Values are mean unless marked with ∼=median.
*p<0.05.
†Values are mean unless marked with ∼=median.
‡Patients without hypertension, diabetes and cardiovascular heart disease.
###Newly diagnosed untreated patients without hypertension, diabetes and cardiovascular heart disease.
§Frequency of systolic dysfunction not presented.
††Newly diagnosed untreated patients.
DM, dermatomyositis; e0, early diastolic tissue velocity; E, early diastolic transmitral flow; NA, not available; EF, ejection fraction; F/M, female/male; IIM, idiopathic inflammatory myopathy; JDM,
juvenile dermatomyositis; LV, left ventricular; PM, polymyositis.
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Table 3 Methods of cardiac assessment in IIM
Methods Advantages Disadvantages Used in IIM
ECG Can detect ST segment and T wave abnormalities,
arrhythmias and conduction abnormalities. May also give
indications of left ventricular hypertrophy. Readily available
Some false positive and negative results. Clinical significance
often unclear.
Many studies,
eg, 6–8
24 hour
ECG/Holter monitoring
Can detect arrhythmias, heart rate variability and ischaemia Requires more resources than standard ECG 18 21 70
Echo-cardiography Can assess wall thickness, size of the four chambers, valve
structure, systolic and diastolic function. Strain imaging and
tissue doppler are newer methods used to assess cardiac
function.
Operator dependent. Low sensitivity for detection of myocardial
inflammation and fibrosis
14–18 21 57
Endomyocardial
biopsy
Gold standard for detecting myocardial inflammation and
fibrosis. Remains a choice for selected patients based on
clinical indication.
Unreliable if patchy lesions. Owing to high risk of
complications, biopsies are usually considered unethical in
studies
No clinical
data in IIM
Cardiac MR (CMR) Can image cardiac structure and function from any projection.
Primary imaging modality when diffuse or localised myocardial
fibrosis (late gadolinium enhancement or T1 mapping), or
myocarditis (T weighted, T1 mapping or early gadolinium
enhancement) is suspected.
Time-consuming
Requires expensive technology
Limited availability
19 21 67 68
Cardiac 99mTc-PYP
scintigraphy
Can detect and quantify inflammation of the myocardium by
increased 99mTc-PYP uptake
Requires supplementary CT to image structures.
Time-consuming. Limited availability
18 20 21
CT Can assess coronary artery calcification (CAC score). Good
negative predictive value.
Radiation 22
Creatine Kinase (CK) Available and cheap
A CK-MB/CK total—ratio >3% usually indicates cardiac
damage
In IIM, this ratio might be elevated even without cardiac
involvement
95, used in
most IIM
studies
Troponins
Troponin I
Troponin T
Serum markers specific to myocardial damage, and are
therefore preferred to detect cardiac involvement. Troponin I
most specific to the myocardium
Expressed in fetal skeletal muscle and in healthy or
regenerating adult skeletal muscle. Both troponin-T and
troponin-I can be elevated in the presence of renal failure
79 95–98
B-type natriuretic
peptide
(BNP)
Marker of heart failure Can be elevated in the presence of renal failure No data in IIM
IIM, idiopathic inflammatory myopathies.
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For IBM, few data exist. In a recent Norwegian
population-based study with a mean disease duration of
5.5 years, the mortality due to heart failure and myocar-
dial infarction was higher in those with IBM (8/31,
26%) than in those with PM and DM (4/56, 7%).
However, the patients with IBM were older (66.9 (0.9)
versus 53.2 (1.5) years).31 To the best of our knowledge,
no studies address the relationship between JDM and
coronary artery disease.
An accelerated process of atherosclerosis is evident in
patients with IIM, and seems to be an important aspect
in the development of cardiac involvement,22 41 65 as it
is in RA66 and SLE.3 In addition, the higher burden of
atherosclerosis appears to be associated with the
increased presence of traditional cardiovascular risk
factors.22 Taken together, clinicians should be aware of
symptoms that can be caused by coronary artery disease
in patients with IIM.
Myocarditis
Myocarditis is highlighted as a probable and intriguing
mechanism for cardiac dysfunction in IIM, since inﬂam-
mation similar to that seen in skeletal muscle also can
occur in heart muscle (ﬁgure 1). Through a comprehen-
sive literature search in 2011, Gupta et al24 found cardiac
biopsy data on 68 patients with IIM (including patients
with juvenile onset disease) almost exclusively autopsy
based. In 1979 and 1982, two series showed myocarditis
in 6 of 20 (30%) and 4 of 16 (25%) patients with DM and
PM, respectively.12 13 Mononuclear cell inﬁltrates were
localised to the endomysium and perivascular areas of
the heart muscle, with or without small vessel disease and
replacement ﬁbrosis; this resembled the inﬂammation in
skeletal muscle. Inﬁltrates were also found in the conduc-
tion system.13 The remaining of the 68 patients reviewed
by Gupta et al were described in three studies and eight
case reports.24 Nevertheless, among these unsystematic-
ally selected patients, as many as 38% had myocarditis
and 41% myocardial ﬁbrosis, suggesting a possible
involvement of the heart muscle in patients with IIM.
CMR gives the opportunity of non-invasive investigation
of cardiac inﬂammation. Recent uncontrolled data
showed a high proportion (62–75%) of patients with IIM
with pathological myocardial enhancement, resembling
inﬂammation and ﬁbrosis.19 67 68 Also, in a recent case
report, MRI mapping techniques detected myocardial
oedema.69 99mTechnetium pyrophosphate (99mTc-PYP)
scintigraphy is also capable of detecting cardiac muscle
involvement, and increased myocardium PYP-uptake,
indicative of inﬂammation, was observed in 57% of
patients with PM/DM.20 Two patients with high
PYP-uptake and corresponding left ventricular dysfunc-
tion died. Autopsy showed inﬂammation, degeneration
and ﬁbrosis of the myocardium in accordance with PYP
scintigraphy results. A controlled study has recently estab-
lished a correlation between the magnitudes of myocar-
dium PYP-uptake and diastolic dysfunction of the heart,
which strongly suggests inﬂammation to be a signiﬁcant
contributor to cardiac involvement in IIM.18 However,
these ﬁndings were subclinical and further prospective
studies are desirable. We suggest considering MRI and/
or (99mTc-PYP) scintigraphy as part of the clinical evalu-
ation of patients with IIM if myocarditis is suspected.
Arrhythmia and heart rate variability
Conduction abnormalities on ECG is the most prevalent
evidence of cardiac involvement reported in IIM
(ﬁgure 1). In the late 1970s/1980s, several uncontrolled
studies reported ECG changes like non-speciﬁc ST-T wave
changes, conduction abnormalities or premature ventricu-
lar beats in 32–52% of patients with IIM (13–77 patients)
without clinical signs of cardiac disease.6–8 34 In an autopsy
study, as many as 13/18 (72%) had ECG changes assessed
retrospectively.12 In a Danish study from 2015, patients
with adult PM/DM had longer QTc intervals compared
with controls,18 even though the prevalence of patho-
logical QTc was comparable. Pathologically prolonged
QTc is a known predictor for cardiac arrhythmias and
sudden death. Further studies are needed to clarify the
clinical relevance of longer QTc in IIM. A recent
Norwegian study demonstrated that patients with JDM
examined after a median disease duration of 17 years had
more prevalent ECG abnormalities 23/59 (39%) com-
pared to age-matched and sex-matched controls.16
In a subset of the same Norwegian JDM cohort (after a
median disease duration of 13.5 years), heart rate vari-
ability (HRV) was lower in patients than controls assessed
by Holter ECG.70 Low HRV indicates autonomic dysfunc-
tion, and is associated with increased risk of cardiac
events and death in the general population.71 Autonomic
dysfunction by HRV has, to the best of our knowledge,
not been investigated in the adult onset IIM population.
Taken together, these ﬁndings indicate that even if the
detected ECG abnormalities in IIM are often subclinical,
the associated cardiac involvement can lead to arrhyth-
mias or sudden death.
Pericarditis
Pericarditis in IIM is mostly asymptomatic and haemo-
dynamically insigniﬁcant. It has been found in 4–25% of
adult onset patients with IIM8–11 and 12–15% of patients
with JDM during the disease course.16 72 However, it
may be more common in subgroups of patients with
antisynthetase syndrome (ASS). In a European multicen-
tre study, 9 of 18 anti-PL-7-positive patients (50%) had
pericardial effusion during the disease course.73
Pulmonary hypertension
In IIM, pulmonary hypertension (PH) is probably infre-
quent in the absence of ILD or antisynthetase autoanti-
bodies, but has not been systematically described and
data are mostly limited to case reports or case series.74
The most effective screening method is echocardiog-
raphy, but PH must be conﬁrmed by right heart cath-
eterisation. PH has been conﬁrmed in 8–9% of patients
with ASS in two retrospective series,75 76 mostly
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secondary to ILD. The presence of PH dramatically wor-
sened the prognosis, with a 3-year survival rate of 58%.75
These ﬁndings support that routine screening for PH
should be performed by echocardiography in patients
with ASS at diagnosis and then annually as recom-
mended in patients with systemic sclerosis.77 Screening
is important since PH can lead to right ventricular
failure, a life-threatening complication.
METHODS OF CARDIAC ASSESSMENTS
There are several methods available for assessment of
cardiac structure and function.78 The most important
methods, their advantages and limitations, as well as an
overview of the methods used in IIMs, are shown in table
3. We would like to highlight the opportunities offered by
new echocardiographic methods and by CMR, making
detection of subclinical cardiac dysfunction possible.
Also, cardiac troponin I appears to be speciﬁc to the myo-
cardium, while troponin T is also expressed in skeletal
muscle. Thus, troponin T can be elevated in IIM in the
absence of myocardial involvement.79
PATHOPHYSIOLOGY
Different mechanisms are suspected in the development
of cardiac involvement in IIM. Recently, Wang et al
found dyslipidaemia in newly diagnosed, untreated
patients with PM39 and with DM,38 with lower high-
density lipoprotein cholesterol (HDL-c) and higher tri-
glycerides and total-/HDL cholesterol (TC/HDL) ratio
than matched controls. High TC/HDL ratio is a pre-
dictor of ischaemic heart disease, superior to other lipid
parameters such as TC and HDL/low-density lipoprotein
(LDL).80 Another controlled study of younger patients
with JDM (median age 21.5 years), seen at long-term
(17 years) follow-up, had similar ﬁndings of dyslipidae-
mia.16 High TC/HDL ratio and total cholesterol in the
upper normal range correlated with subclinical cardiac
dysfunction in those with active disease.42 This could
indicate a lowered threshold of harmful cholesterol asso-
ciated effects in active disease. The ‘lipid paradox’ with
increased susceptibility to atherosclerosis with low chol-
esterol levels is even better documented in RA.81 82
Autopsy studies of patients with IIM have shown evi-
dence of inﬂammatory cells in the myocardium,12 18
indicating the presence of myocarditis. Myocarditis can
lead to myocardial ﬁbrosis, which again causes stiffening
of the ventricles (diastolic dysfunction) or arrhythmias
(ﬁgure 1). In the general population, increased serum
levels of proinﬂammatory cytokines are seen with
increasing New York Heart Association-class83 and thus
the degree of heart failure. In a cohort of patients with
JDM, MCP-1 and CCL11 (eotaxin) were elevated and
associated with cardiac dysfunction.42 MCP-1 is known to
induce hypertrophy and myocardial ﬁbrosis in rodents83
and CCL11 ﬁbrosis and myocardial stiffness in rats.84
Myositis speciﬁc and associated autoantibodies (MSA
and MAA) are strong diagnostic tools in IIM, which can
deﬁne phenotypes, including lung involvement.85 An
association between antisignalling recognition particle
(anti-SRP) and cardiac disease has been proposed, but
evidence is weak in adult IIM.24 However, in juvenile
IIM, the presence of anti-SRP was associated with more
frequent abnormal ECG and by echocardiography.86 In
a recent Danish study, the presence of a MSA or MAA
was associated with diastolic dysfunction, although a rela-
tionship between speciﬁc autoantibodies and diastolic
dysfunction was not observed.18
PREVENTION, DIAGNOSTIC WORK-UP/FOLLOW-UP AND
MANAGEMENT
Prevention
Treatment of dyslipidaemia in patients with IIM is
complex. Statins can prevent cardiovascular disease in
the general population. In rare cases, statins can be the
main cause of disease, that is, statin-associated auto-
immune necrotising myopathy.87 A recent study per-
formed by the International Myositis Assessment and
Clinical Studies Group (IMACS) on the use of
lipid-lowering therapy in patients with IIM showed that
76% of the IIM specialists prescribed lipid-lowering
drugs, mostly statins (93%).88 Approximately 10% of the
patients developed worsening of their muscle symptoms,
of which some were reversible on discontinuation of
statin treatment. With the literature available, patients
with IIM should follow the same recommendations for
cardiovascular risk stratiﬁcation and prevention as for
the corresponding general population.89 90 Thus, in
IIM, statins should be used with careful monitoring as
they may worsen muscle symptoms that can be misinter-
preted as a relapse of myositis. Also, clinicians should
keep in mind the lipid paradox described above.
Diagnostic workup and follow-up
If clinical or subclinical cardiac involvement is suspected
based on cardiac symptoms and/or basic cardiac mea-
surements (physical examination, troponin, ECG, etc), a
cardiologist should be involved. A low threshold for
echocardiographic examination should be observed. To
evaluate systolic involvement, we recommend assessing
long axis strain (EF is not sensitive enough), and to
evaluate diastolic involvement we recommend E/é. If
available, we suggest considering MRI and/or
(99mTc-PYP) scintigraphy as part of the clinical evalu-
ation of patients with IIM if myocarditis is suspected.
As a follow-up, it seems reasonable to do yearly ECG,
since ECG changes are the most prevalent evidence of
cardiac involvement reported in IIM. Speciﬁcally, atten-
tion should be paid to prolongation of the QTc interval,
which in turn might call for Holter monitoring to
exclude clinically signiﬁcant ventricular arrhythmia.
Management
Currently, there are no speciﬁc guidelines available for
treatment of heart involvement in myositis. Although
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inﬂammatory changes within the myocardium are
thought to be the cause of reported cardiac dysfunction,
the impact of immunosuppressive therapy is unknown.
However, it is reasonable to assume that an early and sus-
tained reduction in inﬂammation might reduce the risk
of developing diffuse interstitial myocardial ﬁbrosis,
which is important since inﬂammation is treatable, while
ﬁbrosis is thought to be irreversible.
In several case reports, successful pharmacological
treatment of arrhythmia, conduction disorders and
heart failure in children and adults with myositis are
reported.11 48 91 However, it is hard to decide the effect
of the immunosuppressive treatment alone, since these
patients also received antiarrhythmic drugs and heart
failure management depending on their symptoms.
Three studies including 20–44 patients with adult onset
DM/PM show an effect of glucocorticoids plus other
immunosuppressive drugs on clinical or subclinical
heart involvement in the majority of patients.11 68 92
Importantly, heart disease can also occur any time
during the disease course under immunosuppressive
treatment,93 and even in patients in remission.94
Based on case reports, glucocorticoids, either alone or
in combination with other immunosuppressive drugs,
are cornerstones in the treatment of myocarditis. In add-
ition to immunosuppressive therapy, management of
cardiac involvement may require individually tailored
cardiac speciﬁc therapy.
CONCLUDING REMARKS
Similar to other rheumatic diseases, IIM is associated with
an increased risk of cardiac disease: however, the preva-
lence still remains uncertain. The main mechanisms
responsible seem to be atherosclerosis and myocarditis.
New methods of cardiac imaging with ever increasing sen-
sitivity enable us to detect subtle changes of cardiac func-
tion. As physicians, we must use this new insight to give
patients with IIM optimal cardiac care and preventive
treatment; however, consensus guidelines for this do not
yet exist. Also, this new insight challenges us to determine
which ﬁndings have clinical signiﬁcance and, perhaps,
which have not. Therefore, longitudinal follow-up of
patients with IIM with recording of clinical manifestations
of heart involvement is needed. Since these are rare dis-
eases, international collaboration is essential. To support
such collaboration, the Euromyositis Register has been
developed to facilitate longitudinal follow-up of outcome
in patients with IIM, including organ-speciﬁc morbidity
(http://www.euromyositis.net.eu).
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